ゲノム編集の世界市場予測（2022年～2027年）

世界のゲノム編集の市場規模は、2020年の46億400万米ドルから、2027年には140億5,400万米ドルに達し、17.29％のCAGRで成長すると予測されています。

農業や医療分野で活用され、世界的に研究開発が進んでいることや、様々な問題を解決する可能性のあるゲノム編集技術への投資の増加が、予測期間中の市場成長を急伸させると予想されます。さらに、作物の収穫量を向上させるためのゲノム編集の利用に対する世界各地の政府からの支援も、ゲノム編集市場の促進要因と予測されます。

当レポートでは、世界のゲノム編集市場を調査しており、市場の概要、市場の促進要因や抑制要因、技術・用途・エンドユーザー・地域別の分析、競合情勢、企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション

第2章 調査手法

• 調査データ
• 前提条件

第3章 エグゼクティブサマリー

• 調査のハイライト

第4章 市場力学

• 市場促進要因
• 市場抑制要因
• ポーターのファイブフォース分析
  • エンドユーザーの交渉力
  • バイヤーの交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 業界における競合情勢
• 業界のバリューチェーン分析

第5章 ゲノム編集市場分析：技術別

• イントロダクション
• CRISPR（クリスパー）
• TALEN（タレン）
• ZFN（ジンクフィンガーヌクレアーゼ）
• その他

第6章 ゲノム編集市場分析：用途別

• イントロダクション
• 細胞株工学
• 動物遺伝子工学
• 植物遺伝子工学

第7章 ゲノム編集市場分析：エンドユーザー別

• イントロダクション
• 学術・政府系研究機関
• バイオテクノロジー・製薬企業
• 医薬品開発業務受託機関（CRO）

第8章 ゲノム編集市場分析：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • その他
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • その他
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • 台湾
  • タイ
  • インドネシア
  • その他

第9章 競合環境と分析

• 主要企業と戦略分析
• 新興企業と市場の有利性
• 合併、買収、合意、およびコラボレーション
• ベンダー競争力マトリックス

第10章 企業プロファイル

• Thermo Fisher Scientific Inc.
• Merck & Co., Inc.
• Horizon Discovery Group plc
• GenScript
• Sangamo Therapeutics, Inc.
• Integrated DNA Technologies, Inc.
• Lonza Group Ltd.
• BEX Co., LTD.
• OriGene Technologies, Inc.
• Transposagen Biopharmaceuticals, Inc.

The genome editing market was evaluated at US$4.604 billion in the year 2020 and is projected to grow at a CAGR of 17.29% to reach a market size of US$14.054 billion by the year 2027.

Genome editing is a method of making changes in a living organism's DNA and is used for improving crop yields, diagnosing and treating diseases, and for research purposes. The research and development in genome editing have been increasing worldwide as it is being used in the agriculture and healthcare sectors. Also, the investments in genome editing have been rising as the technique is being seen to have the potential to solve various problems, which is anticipated to surge the market growth during the forecast period. Furthermore, the support of various governments worldwide for the use of genome editing to improve crop yields is another prominent factor expected to drive the genome editing market. Moreover, the growing cases of cancer and other genetic disorders are surging the need for effective treatment and consequently leading to the market growth of genome editing.

The COVID-19 pandemic had a positive impact on the market as researchers developed new diagnostic tools based on CRISPR, a genome-editing technique, for diagnosing COVID-19 patients. This led to a positive impact on the genome editing market and increased the expected growth rates of the genome editing market in 2020 and 2021. As the spread of coronavirus continues to affect the world with its new waves and variants, the pandemic is projected to have a positive impact on the genome editing market in the coming years as well.

Growing cases of cancer and other genetic disorders

The cases of cancer and other genetic disorders have been increasing globally. The growing interest in genome editing for the treatment of cancer and several genetic disorders is anticipated to propel the growth of the genome editing market during the forecast period. NIH researchers have recently, in January 2021, found and recognized a new genetic disorder called linkage-specific-deubiquitylation-deficiency-induced embryonic defects syndrome (LINKED) that causes delays in development and hinders the proper formation of heart, facial features, and brain. Such identifications of new genetic disorders also contribute to the rising cases of genetic disorders. Furthermore, cancer cases have been proliferating. According to data from the International Agency for Research on Cancer (IARC), the number of cancer cases in the United Kingdom (England and Wales) has increased from 138,577 in 2010 to 156,444 in 2017 for males and from 130,674 in 2010 to 149,239 in 2017 for females. As per IARC, the number of cancer cases in Europe is projected to jump from 4.398 million in 2020 to 5.323 million in 2040, witnessing an increase of around 21%. In North America, the cases of cancer are projected to reach 3.525 million in 2040, increasing from 2.557 million in 2020, growing by nearly 38%. This is expected to have a positive impact on the genome editing market in the coming years, owing to an increasing need for better cancer treatments.

Rising investments and research in genome editing

In September 2021, the UK government announced its plans to support gene editing in agriculture to support the country's farmers in growing better and more productive crops. The government is making research and development easier. It also aims to make the necessary measures for genome-edited products to reach safely and responsibly to the market. Furthermore, the government of China is backing the use of CRISPR, a genome-editing technique, to improve the food supply in the country. In 2017, the state-owned company of China named ChemChina acquired Syngenta, a Switzerland-based agribusiness company working with CRISPR with an extensive research and development team. China spent $43 billion on the deal, which is the largest amount ever spent by China on buying a foreign company. The investments in genome editing are expected to grow further in the coming years, along with rising research and development, and are anticipated to boost the genome editing market growth during the forecast period.

North America to dominate the global market

Geographically, the North American region is anticipated to hold a significant market share owing to the large investments being made in the region in the field of genome editing. The Asia Pacific region is anticipated to witness substantial growth due to the surging cases of genetic disorders and cancer, along with higher spending on healthcare and research. As per the data from IARC, the number of cancer cases in Asia is projected to grow by more than 59%. Furthermore, the use of CRISPR has been increasing substantially in China, which is further expected to contribute to the market growth in the Asia Pacific.

Segmentation

• By Technology

CRISPR

TALEN

ZFN

Others

• By Application

Cell Line Engineering

Animal Genetic Engineering

Plant Genetic Engineering

• By End-User

Academic & Government Research Institutes

Biotechnology & Pharmaceutical Companies

Contract Research Organizations

• By Geography

North America

• USA
• Canada
• Mexico

South America

• Brazil
• Argentina
• Others

Europe

• Germany
• France
• UK
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• Others

Asia Pacific

• China
• India
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Segmentation

2. Research Methodology

• 2.1. Research Data
• 2.2. Assumptions

3. Executive Summary

• 3.1. Research Highlights

4. Market Dynamics

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of End-Users
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. Genome Editing Market Analysis, by Technology

• 5.1. Introduction
• 5.2. CRISPR
• 5.3. TALEN
• 5.4. ZFN
• 5.5. Others

6. Genome Editing Market Analysis, by Application

• 6.1. Introduction
• 6.2. Cell Line Engineering
• 6.3. Animal Genetic Engineering
• 6.4. Plant Genetic Engineering

7. Genome Editing Market Analysis, by End-User

• 7.1. Introduction
• 7.2. Academic & Government Research Institutes 
• 7.3. Biotechnology & Pharmaceutical Companies
• 7.4. Contract Research Organizations

8. Genome Editing Market Analysis, by Geography

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. UK
  • 8.4.4. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Taiwan
  • 8.6.6. Thailand
  • 8.6.7. Indonesia
  • 8.6.8. Others

9. Competitive Environment and Analysis

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativeness
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. Company Profiles 

• 10.1. Thermo Fisher Scientific Inc.
• 10.2. Merck & Co., Inc.
• 10.3. Horizon Discovery Group plc
• 10.4. GenScript
• 10.5. Sangamo Therapeutics, Inc.
• 10.6. Integrated DNA Technologies, Inc.
• 10.7. Lonza Group Ltd.
• 10.8. BEX Co., LTD.
• 10.9. OriGene Technologies, Inc.
• 10.10. Transposagen Biopharmaceuticals, Inc.